Advisory Committee Review Of Firazyr Canceled
This article was originally published in The Pink Sheet Daily
Executive Summary
Jerini’s hereditary angiodema candidate has a late April user fee date.
You may also be interested in...
Lev Shows Cinryze Prophylactic Data
Cinryze’s single-treatment alternative may help it compete, even as second-to-market for the hereditary angioedema indication.
Lev Shows Cinryze Prophylactic Data
Cinryze’s single-treatment alternative may help it compete, even as second-to-market for the hereditary angioedema indication.
Lev’s Cinryze To Get FDA Blood Products Advisory Committee Review
Treatment for hereditary angioedema faces advisory committee scrutiny as prophylactic treatment, but not acute indication.